Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews · Epilepsy

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Withdrawals due to adverse events · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).

1 finding from 1 review

Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
RR 2.36 [1.59, 3.51]
7 studies · 2524 participants
Low

Withdrawals due to adverse events · people with drug‐resistant focal epilepsy

Pregabalin probably leads to higher treatment withdrawal due to adverse effects compared with placebo (moderate certainty).

1 finding from 1 review

Pregabalin add‐on for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
RR 2.6 [1.86, 3.64]
9 studies · 2663 participants
Moderate